# 2026-16959: FDA Answers FAQs on Brewing Gene Therapy Wonders

2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-08-20, effective 2026-08-20; PRIA reads it as touching household money (as of 2026-08-27).

- Canonical: https://policyrisk.com/federal-register/2026-16959
- As of: 2026-08-27
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-16959
- Title: Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 53879
- Published: 2026-08-20
- Effective: 2026-08-20
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-08-27

## In one line

FDA Answers FAQs on Brewing Gene Therapy Wonders

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.

## Effects PRIA read

- Final FAQ Guidance for CGT Sponsors: benefit, medium. The FDA published a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products" on August 20, 2026, which finalizes the draft dated November 19, 2024. The guidance gives sponsors answers to common development questions across regulatory review; chemis…
- No New Paperwork Burden Declared: benefit, low. The guidance states it contains no new collection of information under the Paperwork Reduction Act. It refers to previously approved FDA information collections with OMB control numbers 0910-0014 and 0910-0338 covering investigational new drug applications, clinical trials and related forms (e.g.,…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-16959 on federalregister.gov](https://www.federalregister.gov/documents/2026/08/20/2026-16959/frequently-asked-questions-developing-potential-cellular-and-gene-therapy-products-final-guidance)
- [2026-16959 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-08-20/pdf/2026-16959.pdf)

## Related
- [Previous: 2026-16958, Center or Scientific Review; Notice of Closed Meetings](https://policyrisk.com/federal-register/2026-16958)
- [Next: 2026-16960, Potency Assessment of Active Immunotherapy Products; Draft Guidance for Industr…](https://policyrisk.com/federal-register/2026-16960)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-16959 (as of 2026-08-27).
